Recent developments in the 340B program reveal legal and financial challenges for stakeholders. Eli Lilly’s 340B data policy is under scrutiny, facing a cease-and-desist order from Missouri’s Attorney General and a lawsuit from Massachusetts hospitals over claims data demands. Concurrently, drug manufacturers, including AbbVie and Bristol Myers Squibb, along with PhRMA, are seeking to intervene in a lawsuit against HRSA’s rebate model, which has drawn criticism from hospitals projecting substantial losses due to proposed payment cuts by CMS. The American Hospital Association has voiced support for the SUSTAIN 340B Act, which aims to codify the program’s purpose and ensure upfront discounts, while also suggesting necessary improvements. These developments reflect ongoing tensions between drug manufacturers and healthcare providers regarding the sustainability and integrity of the 340B program.
Missouri’s AG issued a cease-and-desist, and Massachusetts hospitals sued Eli Lilly over claims data demands.
AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, and PhRMA filed motions to join a lawsuit against HRSA’s rebate model.
Six health systems project losses ranging from $7 million to $109 million annually due to CMS’ proposed payment cuts.
AHA supports the Act’s provisions to codify 340B’s purpose and preserve upfront discounts, while suggesting improvements.
Missouri’s AG issued a cease-and-desist letter to Eli Lilly, demanding an end to its claims data requirement for 340B pricing.
American Hospital Association and others filed a lawsuit against HRSA to stop the 340B rebate model pilot program.
Bipartisan legislation introduced to pause HRSA’s 340B rebate model pilot and require upfront discounts through 2028.
HHS report identifies issues with 340B program’s growth, spread pricing, and its impact on healthcare costs and consolidation.
- Hospitals face potential financial strain from Eli Lilly’s data demands and the loss of 340B discounts.
- Legal liabilities may arise from privacy breaches if hospitals comply with data submission requirements.
- The CMS proposed 340B payment cuts could lead to significant revenue losses for health systems.
- Ongoing lawsuits against HRSA’s rebate model may disrupt hospital operations and financial planning.
- Hospitals can pursue legal actions to push for more favorable 340B program terms.
- Engagement in legislative processes provides a chance to shape future 340B policies and reforms.
- Exploring alternative drug procurement strategies may mitigate financial impacts of 340B changes.
- Participation in advocacy efforts can strengthen hospital positions in ongoing 340B debates.
- Monitor developments in Eli Lilly’s data policy litigation for potential impacts on 340B compliance.
- Engage with policymakers to influence the outcome of the SUSTAIN 340B Act and other legislative efforts.
- Prepare for potential operational changes if HRSA’s rebate model is implemented as planned.
- Review and strengthen data privacy protocols to mitigate risks associated with claims data submissions.
- Missouri AG issued a cease-and-desist letter to Eli Lilly over 340B data demands.
- Massachusetts hospitals filed a lawsuit against Eli Lilly for cutting 340B discounts.
- Eli Lilly’s policy requires hospitals to submit claims data for 340B discounts.
- Five hospitals allege Eli Lilly unlawfully cut off their 340B discounts.
- The lawsuit claims Eli Lilly violated Massachusetts consumer protection laws.
- Hospitals assert Eli Lilly’s demands harm patient care and violate privacy.
- AbbVie, Bristol Myers Squibb, and PhRMA filed motions to join the lawsuit.
- The lawsuit challenges HRSA’s revised 340B Rebate Model Pilot Program.
- Drugmakers want to defend HRSA-approved rebate plans for their drugs.
- Health systems estimate losses from $7 million to $109 million annually.
- CMS proposed cutting 340B payments to ASP minus 33.4%.
- The rule would raise payments for nondrug outpatient services by 8.44%.
- AHA supports codifying 340B’s purpose in the SUSTAIN 340B Act.
- The Act aims to end the 340B rebate model and preserve upfront discounts.
- AHA suggests improvements to ensure the Act’s provisions are workable.
- Missouri AG issued a cease-and-desist letter to Eli Lilly.
- The letter demands an end to claims data requirements for 340B pricing.
- Failure to comply may lead to enforcement action under state law.
- HHS report identifies 340B program’s growth and cost concerns.
- The report cites issues with spread pricing and hospital consolidation.
- Hospitals argue the program supports services for vulnerable patients.
- Washington State Health Care Authority outlines eligibility and requirements for 340B Drug Pricing Program participation.
- Details on qualifying hospitals, health centers, and specialized clinics provided.
- Federal and state requirements exist to avoid duplicate discounts.
| Court | Matter | Date |
|---|---|---|
| D. Mass. | Massachusetts hospitals v. Eli Lilly (claims data demands lawsuit) [source] | October 27, 2026 |
| D. Me. | American Hospital Association v. Kennedy (340B rebate lawsuit) [source] | October 16, 2026 |
| Manufacturer | Action | Date |
|---|---|---|
| Eli Lilly | Requires 340B hospitals to submit claims data for discounts. [source] | October 27, 2026 |
- Outcome of Massachusetts hospitals’ lawsuit against Eli Lilly over 340B data demands. [source]
- Potential enforcement action by Missouri AG against Eli Lilly for 340B data policy. [source]
- Congressional action on the SUSTAIN 340B Act and its impact on the program. [source]
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.